Literature DB >> 8276672

Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies.

D J Stewart1, J M Molepo, L Eapen, V A Montpetit, R Goel, P T Wong, P Popovic, K D Taylor, G P Raaphorst.   

Abstract

PURPOSE: To review the human central nervous system pharmacology of cisplatin, factors that affect cisplatin uptake in tumors, and use alone and with radiation for the treatment of primary brain tumors. METHODS AND MATERIALS: The authors review their own prior published and unpublished experience and data published by other groups on the above issues.
RESULTS: Cisplatin is one of the most active chemotherapy drugs available for the treatment of solid tumors. It is synergistic with several other agents, including radiation. While it attains only low concentrations in the normal central nervous system, concentrations and plasma-tissue transfer constants for human intracerebral tumors are comparable to those in extracerebral tumors. Tumor type appears to be a more important determinant of platinum concentration than is tumor location, and gliomas do achieve lower concentrations than do other intracerebral or extracerebral tumors. Several other factors have also been identified that correlate with concentrations of cisplatin achieved in human tumors. While cisplatin alone and in combination with other drugs does have some degree of efficacy against primary brain tumors, combining it with cranial irradiation has generally not resulted in any substantial improvement in outcome to date, although some individual studies have been somewhat encouraging. New approaches are currently under investigation.
CONCLUSION: Human pharmacology studies provide a rationale for use of cisplatin in the treatment of human brain tumors, and human and in vitro studies suggest some manipulations that might potentially further augment tumor platinum concentrations. While clinical studies suggest that cisplatin combinations may be of some value vs. human primary brain tumors and brain metastases, and while in vitro studies suggest that cisplatin potentiates radiation efficacy, no combination of cisplatin plus radiation yet tested has appeared to be superior to radiation alone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8276672     DOI: 10.1016/0360-3016(94)90082-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Primary intracerebral osteosarcoma: a case report.

Authors:  G S Bauman; W M Wara; S F Ciricillo; R L Davis; S Zoger; M S Edwards
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

2.  Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors.

Authors:  Weilian Yang; Tianyao Huo; Rolf F Barth; Nilendu Gupta; Michael Weldon; John C Grecula; Brian D Ross; Benjamin A Hoff; Ting-Chao Chou; Julia Rousseau; Hélène Elleaume
Journal:  J Neurooncol       Date:  2010-06-25       Impact factor: 4.130

3.  Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.

Authors:  P Bergström; A Johnsson; T Bergenheim; R Henriksson
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 4.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.

Authors:  D J Stewart; G P Raaphorst; J Yau; A R Beaubien
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice.

Authors:  Shuang Liu; Xing Wen; Qihan Huang; Minghui Zhu; Jun Lu
Journal:  Antioxidants (Basel)       Date:  2022-06-10

Review 6.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Tumoricidal activity of low-energy 160-KV versus 6-MV X-rays against platinum-sensitized F98 glioma cells.

Authors:  Sara N Lim; Anil K Pradhan; Rolf F Barth; Sultana N Nahar; Robin J Nakkula; Weilian Yang; Alycia M Palmer; Claudia Turro; Michael Weldon; Erica Hlavin Bell; Xiaokui Mo
Journal:  J Radiat Res       Date:  2014-09-28       Impact factor: 2.724

9.  Pressure tuning infrared spectroscopic study of cisplatin-induced structural changes in a phosphatidylserine model membrane.

Authors:  K D Taylor; R Goel; F H Shirazi; M Molepo; P Popovic; D J Stewart; P T Wong
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

10.  Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.

Authors:  D J Stewart; J M Molepo; R M Green; V A Montpetit; H Hugenholtz; A Lamothe; N Z Mikhael; M D Redmond; M Gadia; R Goel
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.